Literature DB >> 12547996

Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities.

Kenji Harada1, Masahiro Nomura, Akiyoshi Nishikado, Kouzoh Uehara, Yutaka Nakaya, Susumu Ito.   

Abstract

Dihydropyridine Ca antagonists cause reflex tachycardia related to their hypotensive effects. Efonidipine hydrochloride has inhibitory effects on T-type Ca channels, even as it inhibits reflex tachycardia. In the present study, the influence of efonidipine hydrochloride on heart rate and autonomic nervous function was investigated. Using an electrocardiogram and a tonometric blood pressure measurement, autonomic nervous activity was evaluated using spectral analysis of heart rate/systolic blood pressure variability. Three protocols were used: (1) a single dose of efonidipine hydrochloride was administered orally to healthy subjects with resting heart rate values of 75 beats/min or more (high-HR group) and to healthy subjects with resting heart rate values less than 75 beats/min (low-HR group); (2) efonidipine hydrochloride was newly administered to untreated patients with essential hypertension, and autonomic nervous activity was investigated after a 4-week treatment period; and (3) patients with high heart rate values (>/=75 beats/min) who had been treated with a dihydropyridine L-type Ca channel inhibitor for 1 month or more were switched to efonidipine hydrochloride and any changes in autonomic nervous activity were investigated. In all protocols, administration of efonidipine hydrochloride decreased the heart rate in patients with a high heart rate, reduced sympathetic nervous activity, and enhanced parasympathetic nervous activity. In addition, myocardial scintigraphy with (123)I-metaiodobenzylguanidine showed significant improvement in the washout rate and H/M ratio of patients who were switched from other dihydropyridine Ca antagonists to efonidipine hydrochloride. Efonidipine hydrochloride inhibits increases in heart rate and has effects on the autonomic nervous system. It may be useful for treating hypertension and angina pectoris, and may also have a cardiac protective function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547996     DOI: 10.1253/circj.67.139

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

Review 1.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

Review 2.  Manidipine: a review of its use in the management of hypertension.

Authors:  Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

4.  Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels.

Authors:  Taiji Furukawa; Reiko Miura; Mitsuyoshi Honda; Natsuko Kamiya; Yasuo Mori; Satoshi Takeshita; Takaaki Isshiki; Toshihide Nukada
Journal:  Br J Pharmacol       Date:  2004-11-15       Impact factor: 8.739

5.  L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB.

Authors:  Michio Fukuda; Yoshiaki Ogiyama; Ryo Sato; Toshiyuki Miura; Hidekatsu Fukuta; Masashi Mizuno; Ken Kiyono; Yoshiharu Yamamoto; Junichiro Hayano; Nobuyuki Ohte
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-04-18       Impact factor: 1.636

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.